About this Journal Submit a Manuscript Table of Contents
Parkinson’s Disease
Volume 2012 (2012), Article ID 943159, 15 pages
http://dx.doi.org/10.1155/2012/943159
Review Article

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease

Department of Neurosurgery and Neurology, Clinica Universidad de Navarra, 31008 Pamplona, Spain

Received 6 May 2012; Accepted 8 August 2012

Academic Editor: Anna Rosa Carta

Copyright © 2012 J. Guridi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Barbeau, “Long term assessment of levodopa therapy in Parkinson's disease,” Canadian Medical Association Journal, vol. 112, no. 12, pp. 1379–1380, 1975. View at Scopus
  2. C. D. Marsden and J. D. Parkes, “Success and problems of long term levodopa therapy in Parkinson's disease,” The Lancet, vol. 1, no. 8007, pp. 345–349, 1977. View at Scopus
  3. J. A. Obeso, F. Grandas, J. Vaamonde et al., “Motor complications associated with chronic levodopa therapy in Parkinson's disease,” Neurology, vol. 39, supplement 2, no. 11, pp. 11–19, 1989. View at Scopus
  4. M. R. Luquin, O. Scipioni, J. Vaamonde, O. Gershanik, and J. A. Obeso, “Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification,” Movement Disorders, vol. 7, no. 2, pp. 117–124, 1992. View at Scopus
  5. O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, and A. E. Lang, “A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa,” The New England Journal of Medicine, vol. 342, no. 20, pp. 1484–1491, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Obeso, M. C. Rodriguez-Oroz, M. Rodriguez, M. R. DeLong, and C. W. Olanow, “Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model,” Annals of Neurology, vol. 47, no. 4, pp. S22–S34, 2000. View at Scopus
  7. E. Růžička, K. Zárubová, J. G. Nutt, and B. R. Bloem, “‘Silly Walks’ in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias,” Movement Disorders, vol. 26, no. 9, pp. 1783–1784, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. R. Freed, P. E. Greene, R. E. Breeze, et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” The New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Limousin, P. Krack, P. Pollak, et al., “Electrical stimulatiion of the subthalamic nucleus in advanced Parekinson's disease,” The New England Journal of Medicine, vol. 339, no. 16, pp. 1105–1111, 1998.
  10. C. W. Olanow, J. H. Kordower, A. E. Lang, and J. A. Obeso, “Dopaminergic transplantation for Parkinson's disease: current status and future prospects,” Annals of Neurology, vol. 66, no. 5, pp. 591–596, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. W. Olanow, J. M. Gracies, C. G. Goetz et al., “Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: a double blind video-based analysis,” Movement Disorders, vol. 24, no. 3, pp. 336–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. W. Olanow, A. H. V. Schapira, and O. Rascol, “Continuous dopamine-receptor stimulation in early Parkinson's disease,” Trends in Neurosciences, vol. 23, supplement 10, pp. S117–S126, 2000. View at Scopus
  13. M. A. Cenci, C. S. Lee, and A. Björklund, “L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA,” European Journal of Neuroscience, vol. 10, no. 8, pp. 2694–2706, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Calabresi, M. D. Filippo, V. Ghiglieri, N. Tambasco, and B. Picconi, “Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap,” The Lancet Neurology, vol. 9, no. 11, pp. 1106–1117, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Filion, L. Tremblay, and P. J. Bedard, “Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism,” Brain Research, vol. 547, no. 1, pp. 152–161, 1991. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Papa, R. Desimone, M. Fiorani, and E. H. Oldfield, “Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias,” Annals of Neurology, vol. 46, no. 5, pp. 732–738, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Levy, J. O. Dostrovsky, A. E. Lang, E. Sime, W. D. Hutchison, and A. M. Lozano, “Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease,” Journal of Neurophysiology, vol. 86, no. 1, pp. 249–260, 2001. View at Scopus
  18. A. M. Lozano, A. E. Lang, R. Levy, W. Hutchison, and J. Dostrovsky, “Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine,” Annals of Neurology, vol. 47, supplement 1, no. 4, pp. S141–S146, 2000. View at Scopus
  19. M. Merello, J. Balej, M. Delfino, A. Cammarota, O. Betti, and R. Leiguarda, “Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease,” Movement Disorders, vol. 14, no. 1, pp. 45–49, 1999. View at Scopus
  20. I. J. Mitchell, S. Boyce, M. A. Sambrook, and A. R. Crossman, “A 2-deoxyglucose study of the effects of dopamine agonists on the Parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia,” Brain, vol. 115, pp. 809–824, 1992. View at Scopus
  21. R. L. Albin, “The pathophysiology of chorea/ballism and Parkinsonism,” Parkinsonism and Related Disorders, vol. 1, no. 1, pp. 3–11, 1995. View at Scopus
  22. R. L. Albin, A. B. Young, and J. B. Penney, “The functional anatomy of basal ganglia disorders,” Trends in Neurosciences, vol. 12, no. 10, pp. 366–375, 1989. View at Scopus
  23. A. R. Crossman, “Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders,” Neuroscience, vol. 21, no. 1, pp. 1–40, 1987. View at Scopus
  24. M. R. DeLong, “Primate models of movement disorders of basal ganglia origin,” Trends in Neurosciences, vol. 13, no. 7, pp. 281–285, 1990. View at Scopus
  25. A. R. Crossman, I. J. Mitchell, M. A. Sambrook, and A. Jackson, “Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea,” Brain, vol. 111, pp. 1211–1233, 1988. View at Scopus
  26. I. Hamada and M. R. DeLong, “Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs,” Journal of Neurophysiology, vol. 68, no. 5, pp. 1850–1858, 1992. View at Scopus
  27. I. J. Mitchell, A. Jackson, M. A. Sambrook, and A. R. Crossman, “The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies,” Brain, vol. 112, pp. 1533–1548, 1989. View at Scopus
  28. A. Berthet, E. Bezard, G. Porras, et al., “L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor,” Journal of Neuroscience, vol. 32, no. 2, pp. 681–691, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. M. Iravani, A. C. McCreary, and P. Jenner, “Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia,” Parkinsonism and Related Disorders, vol. 181, supplement 1, pp. S123–S125, 2012.
  30. I. Aubert, C. Guigoni, K. Håkansson et al., “Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia,” Annals of Neurology, vol. 57, no. 1, pp. 17–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Bordet, S. Ridray, J. C. Schwartz, and P. Sokoloff, “Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats,” European Journal of Neuroscience, vol. 12, no. 6, pp. 2117–2123, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Guigoni, S. Dovero, I. Aubert et al., “Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning,” European Journal of Neuroscience, vol. 22, no. 1, pp. 283–287, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Picconi, D. Centonze, K. Håkansson et al., “Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia,” Nature Neuroscience, vol. 6, no. 5, pp. 501–506, 2003. View at Scopus
  34. A. Berthet, G. Porras, E. Doudnikoff et al., “Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia,” Journal of Neuroscience, vol. 29, no. 15, pp. 4829–4835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Bézard, S. Ferry, U. Mach et al., “Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function,” Nature Medicine, vol. 9, no. 6, pp. 762–767, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Fiorentini, C. Busi, E. Gorruso, C. Gotti, P. Spano, and C. Missale, “Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization,” Molecular Pharmacology, vol. 74, no. 1, pp. 59–69, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Smith, D. Raju, B. Nanda, J. F. Pare, A. Galvan, and T. Wichmann, “The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states,” Brain Research Bulletin, vol. 78, no. 2-3, pp. 60–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. M. Villalba and Y. Smith, “Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease,” Frontiers in Systems Neuroscience, vol. 5, article 68, 2011.
  39. F. Gardoni, B. Picconi, V. Ghiglieri et al., “A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia,” Journal of Neuroscience, vol. 26, no. 11, pp. 2914–2922, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. H. S. Bateup, E. Santini, W. Shen et al., “Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 33, pp. 14845–14850, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. V. Ghiglieri, B. Picconi, and P. Calabresi, “Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance,” Movement Disorders, vol. 25, no. 11, pp. 1527–1529, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Belujon, D. J. Lodge, and A. A. Grace, “Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment,” Movement Disorders, vol. 25, no. 11, pp. 1568–1576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. R. Aron and J. Obeso, “Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia?” Movement Disorders, vol. 27, no. 3, pp. 339–340, 2012.
  44. I. Shoulson, “DATATOP: a decade of neuroprotective inquiry,” Annals of Neurology, vol. 44, supplement 1, no. 3, pp. S160–S166, 1998. View at Scopus
  45. O. Rascol, D. J. Brooks, A. D. Korczyn, et al., “Development of dyskinesias in a 5-year trial and ropinirole and L-dopa,” Movement Disorders, vol. 21, no. 11, pp. 1844–1850, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. R. A. Hauser, O. Rascol, A. D. Korczyn et al., “Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa,” Movement Disorders, vol. 22, no. 16, pp. 2409–2417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. R. L. Watts, K. E. Lyons, R. Pahwa et al., “Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease,” Movement Disorders, vol. 25, no. 7, pp. 858–866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. E. C. Maratos, M. J. Jackson, R. K. B. Pearce, and P. Jenner, “Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus),” Movement Disorders, vol. 16, no. 4, pp. 631–641, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Holloway, “A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study,” Clinical Neuropharmacology, vol. 23, no. 1, pp. 34–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Holloway, K. Marek, K. Biglan et al., “Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease,” Archives of Neurology, vol. 66, no. 5, pp. 563–570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Bracco, A. Battaglia, C. Chouza et al., “The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study,” CNS Drugs, vol. 18, no. 11, pp. 733–746, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Inzelberg, E. Schechtman, and P. Nisipeanu, “Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison,” Drugs and Aging, vol. 20, no. 11, pp. 847–855, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Pinero, P. Marcos-Alberca, and J. Fortes, “Cabergoline-related severe restrictive mitral regurgitation,” The New England Journal of Medicine, vol. 353, no. 18, pp. 1976–1977, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. V. Voon, P. O. Fernagut, J. Wickens et al., “Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders,” The Lancet Neurology, vol. 8, no. 12, pp. 1140–1149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Bélanger, L. Grégoire, A. H. Tahar, and P. J. Bédard, “Chronic treatment with small does of cabergoline prevents dopa-induced dyskinesias in Parkinsonian monkeys,” Movement Disorders, vol. 18, no. 12, pp. 1436–1441, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Pirtosek, M. Merello, A. Carlsson, and G. Stern, “Preclamol and parkinsonian fluctuations,” Clinical Neuropharmacology, vol. 16, no. 6, pp. 550–554, 1993. View at Scopus
  57. J. A. Lieberman, “Dopamine partial agonists: a new class of antipsychotic,” CNS Drugs, vol. 18, no. 4, pp. 251–267, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Meco, P. Stirpe, F. Edito et al., “Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study,” Journal of Neural Transmission, vol. 116, no. 7, pp. 881–884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. J. D. Oh, F. Bibbiani, and T. N. Chase, “Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models,” Experimental Neurology, vol. 177, no. 2, pp. 557–564, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. R. Katzenschlager, A. J. Manson, A. Evans, H. Watt, and A. J. Lees, “Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 2, pp. 295–297, 2004. View at Scopus
  61. F. Durif, B. Debilly, M. Galitzky et al., “Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study,” Neurology, vol. 62, no. 3, pp. 381–388, 2004. View at Scopus
  62. L. V. Metman, P. Del Dotto, P. J. Blanchet, P. Van Den Munckhof, and T. N. Chase, “Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease,” Amino Acids, vol. 14, no. 1–3, pp. 75–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Del Dotto, N. Pavese, G. Gambaccini et al., “Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study,” Movement Disorders, vol. 16, no. 3, pp. 515–520, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Luginger, G. K. Wenning, S. Bösch, and W. Poewe, “Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease,” Movement Disorders, vol. 15, no. 5, pp. 873–878, 2000. View at Scopus
  65. B. J. Snow, L. Macdonald, D. Mcauley, and W. Wallis, “The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study,” Clinical Neuropharmacology, vol. 23, no. 2, pp. 82–85, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Thomas, D. Iacono, A. L. Luciano, K. Armellino, A. Di Iorio, and M. Onofrj, “Duration of amantadine benefit on dyskinesia of severe Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 1, pp. 141–143, 2004. View at Scopus
  67. M. Merello, S. Perez-Lloret, J. Antico, and J. A. Obeso, “Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 77, no. 2, pp. 172–174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Merello, M. I. Nouzeilles, A. Cammarota, and R. Leiguarda, “Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study,” Clinical Neuropharmacology, vol. 22, no. 5, pp. 273–276, 1999. View at Scopus
  69. J. Lökk, “Memantine can relieve certain symptoms in Parkinson's disease,” Lakartidningen, vol. 101, no. 23, pp. 2003–2006, 2004. View at Scopus
  70. S. Varanese, J. Howard, and A. Di Rocco, “NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson's disease,” Movement Disorders, vol. 25, no. 4, pp. 508–510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. C. A. Braz, V. Borges, and H. B. Ferraz, “Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study,” Clinical Neuropharmacology, vol. 27, no. 1, pp. 25–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. W. Bara-Jimenez, T. D. Dimitrova, A. Sherzai, M. Aksu, and T. N. Chase, “Glutamate release inhibition ineffective in levodopa-induced motor complications,” Movement Disorders, vol. 21, no. 9, pp. 1380–1383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. F. Durif, M. Vidailhet, A. M. Bonnet, J. Blin, and Y. Agid, “Levodopa-induced dyskinesias are improved by fluoxetine,” Neurology, vol. 45, no. 10, pp. 1855–1858, 1995. View at Scopus
  74. B. Kleedorfer, A. J. Lees, and G. M. Stern, “Buspirone in the treatment of levodopa induced dyskinesias,” Journal of Neurology Neurosurgery and Psychiatry, vol. 54, no. 4, pp. 376–377, 1991. View at Scopus
  75. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco, “Buspirone in levodopa-induced dyskinesias,” Clinical Neuropharmacology, vol. 17, no. 1, pp. 73–82, 1994. View at Scopus
  76. G. Meco, E. Fabrizio, S. Di Rezze, A. Alessandri, and L. Pratesi, “Mirtazapine in L-dopa-induced dyskinesias,” Clinical Neuropharmacology, vol. 26, no. 4, pp. 179–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Samadi, L. Grégoire, and P. J. Bédard, “The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys,” Neurobiology of Disease, vol. 16, no. 1, pp. 246–253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. J. B. Koprich, S. H. Fox, T. H. Johnston et al., “The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease,” Movement Disorders, vol. 26, no. 7, pp. 1225–1233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. B. Carroll, P. O. Bain, L. Teare et al., “Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study,” Neurology, vol. 63, no. 7, pp. 1245–1250, 2004. View at Scopus
  80. A. F. Carpentier, A. M. Bonnet, M. Vidailhet, and Y. Agid, “Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease,” Neurology, vol. 46, no. 6, pp. 1548–1551, 1996. View at Scopus
  81. K. Buck, P. Voehringer, and B. Ferger, “The α2 adrenoceptor antagonist idazoxan alleviates l-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats,” Journal of Neurochemistry, vol. 112, no. 2, pp. 444–452, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Grondin, A. H. Tahar, V. D. Doan, P. Ladure, and P. J. Bédard, “Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 361, no. 2, pp. 181–186, 2000. View at Publisher · View at Google Scholar · View at Scopus
  83. O. Rascol, I. Arnulf, H. Peyro-Saint Paul et al., “Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease,” Movement Disorders, vol. 16, no. 4, pp. 708–713, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. M. D. Gottwald and M. J. Aminoff, “Therapies for dopaminergic-induced dyskinesias in Parkinson disease,” Annals of Neurology, vol. 69, no. 6, pp. 919–927, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Müller, “New small molecules for the treatment of Parkinson's disease,” Expert Opinion on Investigational Drugs, vol. 19, no. 9, pp. 1077–1086, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. D. J. Brooks, S. Papapetropoulos, F. Vandenhende et al., “An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers,” Clinical Neuropharmacology, vol. 33, no. 2, pp. 55–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Jankovic, “Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?” Annals of Neurology, vol. 63, no. 3, pp. 267–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Pourcher, H. H. Fernandez, M. Stacy, A. Mori, R. Ballerini, and P. Chaikin, “Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study,” Parkinsonism and Related Disorders, vol. 18, no. 2, pp. 178–184, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. H. H. Fernandez, D. R. Greeley, R. M. Zweig, J. Wojcieszek, A. Mori, and N. M. Sussman, “Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial,” Parkinsonism and Related Disorders, vol. 16, no. 1, pp. 16–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. R. A. Hauser, L. M. Shulman, J. M. Trugman et al., “Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations,” Movement Disorders, vol. 23, no. 15, pp. 2177–2185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Stacy, D. Silver, T. Mendis et al., “A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease,” Neurology, vol. 70, no. 23, pp. 2233–2240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. P. A. LeWitt, M. Guttman, J. W. Tetrud et al., “Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005),” Annals of Neurology, vol. 63, no. 3, pp. 295–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. R. A. Hauser, M. Cantillon, E. Pourcher et al., “Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial,” The Lancet Neurology, vol. 10, no. 3, pp. 221–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. M. Contin, P. Martinelli, F. Albani et al., “Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias,” Clinical Neuropharmacology, vol. 30, no. 2, pp. 122–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. K. E. Lyons and R. Pahwa, “Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia,” Clinical Neuropharmacology, vol. 29, no. 3, pp. 148–153, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Wolz, M. Löhle, K. Strecker et al., “Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial,” Journal of Neural Transmission, vol. 117, no. 11, pp. 1279–1286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. K. K. Wong, J. E. Alty, A. G. Goy, S. Raghav, D. C. Reutens, and P. A. Kempster, “A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease,” Movement Disorders, vol. 26, no. 8, pp. 1552–1555, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. T. A. Zesiewicz, K. L. Sullivan, J. L. Maldonado, W. O. Tatum, and R. A. Hauser, “Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease,” Movement Disorders, vol. 20, no. 9, pp. 1205–1209, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Bronzova, C. Sampaio, R. A. Hauser et al., “Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease,” Movement Disorders, vol. 25, no. 6, pp. 738–746, 2010. View at Scopus
  100. R. A. Hauser, J. Bronzova, C. Sampaio et al., “Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease for the pardoprunox study group,” European Neurology, vol. 62, no. 1, pp. 40–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. O. Rascol, J. Bronzova, R. A. Hauser, et al., “Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial,” Parkinsonism and Related Disorders, vol. 18, no. 4, pp. 370–376, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. F. Stocchi, G. Arnold, M. Onofrj et al., “Improvement of motor function in early Parkinson disease by safinamide,” Neurology, vol. 63, no. 4, pp. 746–748, 2004. View at Scopus
  103. D. Grosset and A. Grosset, “The movement disorder society—14th international congress of Parkinson's disease and movement disorders,” IDrugs, vol. 13, no. 8, pp. 539–542, 2010. View at Scopus
  104. D. Berg, J. Godau, C. Trenkwalder et al., “AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials,” Movement Disorders, vol. 26, no. 7, pp. 1243–1250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Fregni, D. K. Simon, A. Wu, and A. Pascual-Leone, “Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 12, pp. 1614–1623, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. T. N. Chase, F. Baronti, G. Fabbrini, I. J. Heuser, J. L. Juncos, and M. M. Mouradian, “Rationale for continuous dopaminomimetic therapy of Parkinson's disease,” Neurology, vol. 39, supplement 2, no. 11, pp. 7–19, 1989. View at Scopus
  107. R. Horowski, C. D. Marsden, and J. A. Obeso, “Continuous dopaminergic stimulation: state of the art and outlook,” Journal of Neural Transmission, Supplement, vol. 27, pp. 249–252, 1988. View at Scopus
  108. J. A. Obeso, F. Grandas, M. T. Herrero, and R. Horowski, “The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease,” European Journal of Neuroscience, vol. 6, no. 6, pp. 889–897, 1994. View at Publisher · View at Google Scholar · View at Scopus
  109. M. M. Mouradian, I. J. E. Heuser, F. Baronti, and T. N. Chase, “Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease,” Annals of Neurology, vol. 27, no. 1, pp. 18–23, 1990. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Antonini, I. U. Isaias, M. Canesi et al., “Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome,” Movement Disorders, vol. 22, no. 8, pp. 1145–1149, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. D. Devos, “Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease,” Movement Disorders, vol. 24, no. 7, pp. 993–1000, 2009.
  112. D. Nyholm, T. Lewander, A. Johansson, P. A. LeWitt, C. Lundqvist, and S. M. Aquilonius, “Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure,” Clinical Neuropharmacology, vol. 31, no. 2, pp. 63–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. D. Nyholm, A. I. M. Nilsson Remahl, N. Dizdar et al., “Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease,” Neurology, vol. 64, no. 2, pp. 216–223, 2005. View at Scopus
  114. T. Müller, K. Renger, and W. Kuhn, “Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration,” Archives of Neurology, vol. 61, no. 5, pp. 657–660, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Onofrj, L. Bonanni, G. Cossu, D. Manca, F. Stocchi, and A. Thomas, “Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment,” Parkinsonism and Related Disorders, vol. 15, supplement 3, pp. S233–S236, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. G. Block, C. Liss, S. Reines, et al., “Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study,” European Neurology, vol. 37, no. 1, pp. 23–27, 1997. View at Scopus
  117. F. Stocchi, O. Rascol, K. Kieburtz et al., “Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study,” Annals of Neurology, vol. 68, no. 1, pp. 18–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. A. J. Stoessl, “Continuous dopaminergic therapy in Parkinson disease: time to stride back?” Annals of Neurology, vol. 68, no. 1, pp. 3–5, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. R. A. Hauser, A. L. Ellenbogen, L. V. Metman et al., “Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease,” Movement Disorders, vol. 26, no. 12, pp. 2246–2252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Stocchi, S. Ruggieri, L. Vacca, and C. W. Olanow, “Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease,” Brain, vol. 125, pp. 2058–2066, 2002. View at Scopus
  121. J. A. Obeso, M. R. Luquin, and J. M. Martinez-Lage, “Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease,” The Lancet, vol. 1, no. 8479, pp. 467–470, 1986. View at Scopus
  122. J. Vaamonde, M. R. Luquin, and J. A. Obeso, “Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients,” Brain, vol. 114, pp. 601–617, 1991. View at Scopus
  123. A. J. Manson, K. Turner, and A. J. Lees, “Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients,” Movement Disorders, vol. 17, no. 6, pp. 1235–1241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. P. J. García Ruiz, Á. S. Ignacio, B. A. Pensado, et al., “Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study,” Movement Disorders, vol. 23, no. 8, pp. 1130–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. R. Katzenschlager, A. Hughes, A. Evans et al., “Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges,” Movement Disorders, vol. 20, no. 2, pp. 151–157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  126. C. Ohye, T. Maeda, and H. Narabayashi, “Physiologically defined VIM nucleus. Its special reference to control of tremor,” Applied Neurophysiology, vol. 39, no. 3-4, pp. 285–295, 1976. View at Scopus
  127. F. A. Lenz, H. C. Kwan, R. L. Martin, R. R. Tasker, J. O. Dostrovsky, and Y. E. Lenz, “Single unit analysis of the human ventral thalamic nuclear group. Tremor-related activity in functionally identified cells,” Brain, vol. 117, pp. 531–543, 1994. View at Scopus
  128. R. R. Tasker and Z. H. T. Kiss, “The role of the thalamus in functional neurosurgery,” Neurosurgery Clinics of North America, vol. 6, no. 1, pp. 73–104, 1995. View at Scopus
  129. J. M. Van Buren, C. L. Li, and D. Y. Shapiro, “A qualitative and quantitative evaluation of parkinsonians three to six years following thalamotomy,” Confinia Neurologica, vol. 35, no. 4, pp. 202–235, 1973. View at Scopus
  130. J. Husby and A. G. Korsgaard, “Proceedings: late results of thalamotomy in Parkinsonism with and without the influence of levodopa,” Acta Neurochirurgica, vol. 31, no. 3-4, p. 260, 1975. View at Scopus
  131. P. J. Derome, C. P. Jedynak, A. Visot, and O. Delalande, “Treatment of abnormal movements by thalamic lesions,” Revista de Neurología, vol. 142, no. 4, pp. 391–397, 1986.
  132. Y. Nagaseki, T. Shibazaki, and T. Hirai, “Long-term follow-up results of selective VIM-thalamotomy,” Journal of Neurosurgery, vol. 65, no. 3, pp. 296–302, 1986. View at Scopus
  133. M. W. Fox, J. E. Ahlskog, and P. J. Kelly, “Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients,” Journal of Neurosurgery, vol. 75, no. 5, pp. 723–730, 1991. View at Scopus
  134. J. Jankovic, F. Cardoso, R. G. Grossman, W. J. Hamilton, R. R. Tasker, and P. J. Kelly, “Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor,” Neurosurgery, vol. 37, no. 4, pp. 680–687, 1995. View at Scopus
  135. P. J. Kelly and F. J. Gillingham, “The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study,” Journal of Neurosurgery, vol. 53, no. 3, pp. 332–327, 1980. View at Scopus
  136. T. Miyamoto, H. Bekku, E. Moriyama, and S. Tsuchida, “Present role of stereotactic thalamotomy for Parkinsonism. Retrospective analysis of operative results and thalamic lesions in computed tomograms,” Applied Neurophysiology, vol. 48, no. 1–6, pp. 294–304, 1985. View at Scopus
  137. N. Diederich, C. G. Goetz, G. T. Stebbins et al., “Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease,” Neurology, vol. 42, no. 7, pp. 1311–1314, 1992. View at Scopus
  138. H. Narabayashi, F. Yokochi, and Y. Nakajima, “Levodopa-induced dyskinesia and thalamotomy,” Journal of Neurology Neurosurgery and Psychiatry, vol. 47, no. 8, pp. 831–839, 1984. View at Scopus
  139. R. D. Page, M. A. Sambrook, and A. R. Crossman, “Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Parkinsonian monkey,” Neuroscience, vol. 55, no. 1, pp. 147–165, 1993. View at Publisher · View at Google Scholar · View at Scopus
  140. A. L. Benabid, P. Pollak, M. Hommel, J. M. Gaio, J. de Rougemont, and J. Perret, “Treatment of Parkinson tremor by chronic stimulation of the ventral intermediate nucleus of the thalamus,” Revista de Neurología, vol. 145, no. 4, pp. 320–323, 1989.
  141. A. L. Benabid, P. Pollak, E. Seigneuret, D. Hoffmann, E. Gay, and J. Perret, “Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias,” Acta Neurochirurgica, Supplement, vol. 58, pp. 39–44, 1993. View at Scopus
  142. P. Limousin, J. D. Speelman, F. Gielen, and M. Janssens, “Multicentre European study of thalamic stimulation in parkinsonian and essential tremor,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 3, pp. 289–296, 1999. View at Scopus
  143. M. I. Hariz, P. Krack, F. Alesch et al., “Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 6, pp. 694–699, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. R. R. Tasker, M. Munz, F. S. Junn et al., “Deep brain stimulation and thalamotomy for tremor compared,” Acta Neurochirurgica. Supplement, vol. 68, pp. 49–53, 1997. View at Scopus
  145. S. Blond, D. Caparros-Lefebvre, F. Parker et al., “Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus,” Journal of Neurosurgery, vol. 77, no. 1, pp. 62–68, 1992. View at Scopus
  146. D. Caparros-Lefebvre, S. Blond, P. Vermersch, N. Pecheux, J. D. Guieu, and H. Petit, “Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 56, no. 3, pp. 268–273, 1993. View at Scopus
  147. D. Caparros-Lefebvre, S. Blond, M. P. Feltin, P. Pollak, and A. L. Benabid, “Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex,” Journal of Neurology Neurosurgery and Psychiatry, vol. 67, no. 3, pp. 308–314, 1999. View at Scopus
  148. J. L. Lanciego, M. C. Rodríguez-Oroz, F. J. Blesa et al., “Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys,” Movement Disorders, vol. 23, no. 5, pp. 708–715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  149. L. V. Laitinen, A. T. Bergenheim, and M. I. Hariz, “Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease,” Journal of Neurosurgery, vol. 76, no. 1, pp. 53–61, 1992. View at Scopus
  150. M. I. Hariz and A. T. Bergenheim, “A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease,” Journal of Neurosurgery, vol. 94, no. 4, pp. 552–558, 2001. View at Scopus
  151. M. S. Baron, J. L. Vitek, R. A. Bakay et al., “Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study,” Movement Disorders, vol. 15, no. 2, pp. 230–237, 2000.
  152. J. A. Obeso, C. W. Olanow, M. C. Rodriguez-Oroz, P. Krack, R. Kumar, and A. E. Lang, “Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease,” The New England Journal of Medicine, vol. 345, no. 13, pp. 956–963, 2001. View at Publisher · View at Google Scholar · View at Scopus
  153. M. C. Rodriguez-Oroz, J. A. Obeso, A. E. Lang et al., “Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up,” Brain, vol. 128, pp. 2240–2249, 2005. View at Publisher · View at Google Scholar · View at Scopus
  154. J. Volkmann, N. Allert, J. Voges, V. Sturm, A. Schnitzler, and H. J. Freund, “Long-term results of bilateral pallidal stimulation in Parkinson's disease,” Annals of Neurology, vol. 55, no. 6, pp. 871–875, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. E. Moro, A. M. Lozano, P. Pollak et al., “Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease,” Movement Disorders, vol. 25, no. 5, pp. 578–586, 2010. View at Publisher · View at Google Scholar · View at Scopus
  156. L. Alvarez, R. Macias, N. Pavón et al., “Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 9, pp. 979–985, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. P. Krack, P. Pollak, P. Limousin, A. Benazzouz, G. Deuschl, and A. L. Benabid, “From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity,” Brain, vol. 122, pp. 1133–1146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  158. H. Stolze, S. Klebe, M. Poepping et al., “Effects of bilateral subthalamic nucleus stimulation on parkinsonian gait,” Neurology, vol. 57, no. 1, pp. 144–146, 2001. View at Scopus
  159. T. Simuni, J. L. Jaggi, H. Mulholland et al., “Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety,” Journal of Neurosurgery, vol. 96, no. 4, pp. 666–672, 2002. View at Scopus
  160. P. Krack, A. Batir, N. Van Blercom et al., “Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease,” The New England Journal of Medicine, vol. 349, no. 20, pp. 1925–1934, 2003. View at Publisher · View at Google Scholar · View at Scopus
  161. M. C. Rodriguez-Oroz, I. Zamerbide, J. Gyridi, M. R. Palmero, and J. A. Obeso, “Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and label evaluation,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 10, pp. 1382–1385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  162. G. Deuschl, C. Schade-Brittinger, P. Krack, et al., “A randomized trial of deep-brain stimulation for Parkinson's disease,” The New England Journal of Medicine, vol. 355, no. 9, pp. 896–908, 2006.
  163. C. Hamani, E. Richter, J. M. Schwalb, and A. M. Lozano, “Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature,” Neurosurgery, vol. 56, no. 6, pp. 1313–1324, 2005. View at Publisher · View at Google Scholar · View at Scopus
  164. K. A. Follett, “Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias,” Neurosurg Focus, vol. 17, no. 1, p. E3, 2004. View at Scopus
  165. P. Limousin, P. Krack, P. Pollak et al., “Electrical stimulation of the subthalamic nucleus in advanced Parkinsonian's disease,” The New England Journal of Medicine, vol. 339, no. 16, pp. 1105–1111, 1998. View at Publisher · View at Google Scholar · View at Scopus
  166. E. B. Montgomery and K. B. Baker, “Mechanisms of deep brain stimulation and future technical developments,” Neurological Research, vol. 22, no. 3, pp. 259–266, 2000. View at Scopus
  167. F. J. G. Vingerhoets, J. G. Villemure, P. Temperli, C. Pollo, E. Pralong, and J. Ghika, “Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up,” Neurology, vol. 58, no. 3, pp. 396–401, 2002. View at Scopus
  168. H. Russmann, J. Ghika, J. G. Villemure et al., “Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years,” Neurology, vol. 63, no. 10, pp. 1952–1954, 2004. View at Scopus
  169. J. L. Molinuevo, F. Valldeoriola, E. Tolosa et al., “Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease,” Archives of Neurology, vol. 57, no. 7, pp. 983–988, 2000. View at Scopus
  170. R. Figueiras-Mendez, F. Marin-Zarza, J. A. Molina et al., “Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 4, pp. 549–550, 1999. View at Scopus
  171. M. C. Rodriguez-Oroz, A. Gorospe, J. Guridi et al., “Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease,” Neurology, vol. 55, supplement 6, no. 12, pp. S45–S51, 2000. View at Scopus
  172. J. A. Obeso, M. Rodriguez-Oroz, C. Marin, et al., “The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits,” Neurology, vol. 62, supplement 1, no. 1, pp. S17–S30, 2004. View at Scopus
  173. J. A. Saint-Cyr, T. Hoque, L. C. M. Pereira et al., “Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging,” Journal of Neurosurgery, vol. 97, no. 5, pp. 1152–1166, 2002. View at Scopus
  174. J. Voges, J. Volkmann, N. Allert et al., “Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position,” Journal of Neurosurgery, vol. 96, no. 2, pp. 269–279, 2002. View at Scopus
  175. W. Hamel, U. Fietzek, A. Morsnowski et al., “Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 8, pp. 1036–1046, 2003. View at Publisher · View at Google Scholar · View at Scopus
  176. J. Guridi, J. A. Obeso, M. C. Rodriguez-Oroz, A. A. Lozano, and M. Manrique, “L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease,” Neurosurgery, vol. 62, no. 2, pp. 311–323, 2008. View at Publisher · View at Google Scholar · View at Scopus